Literature DB >> 19380599

Sitafloxacin activity against Helicobacter pylori isolates, including those with gyrA mutations.

Kazunari Murakami1, Tadayoshi Okimoto, Masaaki Kodama, Jin Tanahashi, Toshio Fujioka, Fumiaki Ikeda, Hiroe Muraoka, Motoko Takigawa, Takeshi Saika, Miyuki Hasegawa, Intetsu Kobayashi.   

Abstract

Sitafloxacin showed MICs of less than or equal to 0.5 microg/ml against 105 isolates of Helicobacter pylori, including 44 isolates with mutations in the gyrA gene. The highest MICs for garenoxacin and levofloxacin were 8 and 64 times, respectively, higher than the highest MICs observed for sitafloxacin.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19380599      PMCID： PMC2704646          DOI： 10.1128/AAC.01552-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  13 in total

1.  Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756.

Authors:  J C Fung-Tomc; B Minassian; B Kolek; E Huczko; L Aleksunes; T Stickle; T Washo; E Gradelski; L Valera; D P Bonner
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

Review 2.  H pylori antibiotic resistance: prevalence, importance, and advances in testing.

Authors:  F Mégraud
Journal:  Gut       Date:  2004-09       Impact factor: 23.059

Review 3.  Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure.

Authors:  J P Gisbert; F Morena
Journal:  Aliment Pharmacol Ther       Date:  2006-01-01       Impact factor: 8.171

4.  Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report.

Authors:  P Malfertheiner; F Megraud; C O'Morain; F Bazzoli; E El-Omar; D Graham; R Hunt; T Rokkas; N Vakil; E J Kuipers
Journal:  Gut       Date:  2006-12-14       Impact factor: 23.059

5.  Antibacterial activities and inhibitory effects of sitafloxacin (DU-6859a) and its optical isomers against type II topoisomerases.

Authors:  T Akasaka; S Kurosaka; Y Uchida; M Tanaka; K Sato; I Hayakawa
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

6.  Gatifloxacin resistance and mutations in gyra after unsuccessful Helicobacter pylori eradication in Japan.

Authors:  Toshihiro Nishizawa; Hidekazu Suzuki; Kumiko Kurabayashi; Tatsuhiro Masaoka; Hiroe Muraoka; Mikiji Mori; Eisuke Iwasaki; Intetsu Kobayashi; Toshifumi Hibi
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

7.  Levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication.

Authors:  Enrico C Nista; Marcello Candelli; Maria A Zocco; Filippo Cremonini; Veronica Ojetti; Rosalba Finizio; Cristiano Spada; Giovanni Cammarota; Giovanni Gasbarrini; Antonio Gasbarrini
Journal:  Am J Gastroenterol       Date:  2006-09       Impact factor: 10.864

8.  Antimicrobial activity of DU-6859, a new potent fluoroquinolone, against clinical isolates.

Authors:  K Sato; K Hoshino; M Tanaka; I Hayakawa; Y Osada
Journal:  Antimicrob Agents Chemother       Date:  1992-07       Impact factor: 5.191

9.  Antimicrobial susceptibility of Helicobacter pylori isolated from gastric biopsies in dyspeptic patients.

Authors:  Panthong Kulsuntiwong; Chariya Chomvarin; Kunyaluk Chaicumpar; Wises Namwat; Wanlop Kaewkes; Pisaln Mairiang; Apichat Sangchan
Journal:  Southeast Asian J Trop Med Public Health       Date:  2008-11       Impact factor: 0.267

10.  American College of Gastroenterology guideline on the management of Helicobacter pylori infection.

Authors:  William D Chey; Benjamin C Y Wong
Journal:  Am J Gastroenterol       Date:  2007-06-29       Impact factor: 10.864
View more
  14 in total

Review 1.  Treatment of Helicobacter pylori infection: Past, present and future.

Authors:  Vasilios Papastergiou; Sotirios D Georgopoulos; Stylianos Karatapanis
Journal:  World J Gastrointest Pathophysiol       Date:  2014-11-15

Review 2.  Treatment of Helicobacter pylori infection: meeting the challenge of antimicrobial resistance.

Authors:  Vasilios Papastergiou; Sotirios D Georgopoulos; Stylianos Karatapanis
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

3.  Helicobacter pylori first-line and rescue treatments in the presence of penicillin allergy.

Authors:  Javier P Gisbert; Jesús Barrio; Inés Modolell; Javier Molina-Infante; Angeles Perez Aisa; Manuel Castro-Fernández; Luis Rodrigo; Angel Cosme; Jose Luis Gisbert; Miguel Fernández-Bermejo; Santiago Marcos; Alicia C Marín; Adrián G McNicholl
Journal:  Dig Dis Sci       Date:  2014-09-19       Impact factor: 3.199

Review 4.  Current recommendations for Helicobacter pylori therapies in a world of evolving resistance.

Authors:  Francis Mégraud
Journal:  Gut Microbes       Date:  2013-08-05

Review 5.  Helicobacter pylori infection in Japan.

Authors:  Seiji Shiota; Kazunari Murakawi; Rumiko Suzuki; Toshio Fujioka; Yoshio Yamaoka
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2013-01       Impact factor: 3.869

6.  Multi-center randomized controlled study to establish the standard third-line regimen for Helicobacter pylori eradication in Japan.

Authors:  Kazunari Murakami; Takahisa Furuta; Takashi Ando; Takeshi Nakajima; Yoshikatsu Inui; Tadayuki Oshima; Toshihiko Tomita; Katsuhiro Mabe; Makoto Sasaki; Takanori Suganuma; Hideyuki Nomura; Kiichi Satoh; Shinichiro Hori; Syuuji Inoue; Takeshi Tomokane; Mineo Kudo; Tomoki Inaba; Susumu Take; Toshifumi Ohkusa; Shojiro Yamamoto; Shigeaki Mizuno; Toshiro Kamoshida; Kenji Amagai; Junichi Iwamoto; Jun Miwa; Masaaki Kodama; Tadayoshi Okimoto; Mototsugu Kato; Masahiro Asaka
Journal:  J Gastroenterol       Date:  2013-01-11       Impact factor: 7.527

7.  Establishment of a reference panel of Helicobacter pylori strains for antimicrobial susceptibility testing.

Authors:  Kenji Yokota; Takako Osaki; Shunji Hayashi; Shin-Ichi Yokota; Hiroaki Takeuchi; Emiko Rimbara; Hinako Ojima; Toyotaka Sato; Hideo Yonezawa; Keigo Shibayama; Kengo Tokunaga; Shigeru Kamiya; Kazunari Murakami; Mototsugu Kato; Toshiro Sugiyama
Journal:  Helicobacter       Date:  2022-03-07       Impact factor: 5.182

8.  Effective therapeutic regimens in two South Asian countries with high resistance to major Helicobacter pylori antibiotics.

Authors:  Muhammad Miftahussurur; Hafeza Aftab; Pradeep Krishna Shrestha; Rabi Prakash Sharma; Phawinee Subsomwong; Langgeng Agung Waskito; Dalla Doohan; Kartika Afrida Fauzia; Yoshio Yamaoka
Journal:  Antimicrob Resist Infect Control       Date:  2019-02-15       Impact factor: 4.887

9.  Efficacy of Levofloxacin Based Triple and High-Dose PPI-Amoxicillin Dual Eradication Therapy for Helicobacter pylori after Failures of First- and Second-Line Therapies.

Authors:  Kenichiro Okimoto; Makoto Arai; Keiko Saito; Shoko Minemura; Daisuke Maruoka; Tomoaki Matsumura; Tomoo Nakagawa; Tatsuro Katsuno; Chisato Ishii; Shota Murata; Masaharu Watanabe; Fumio Nomura; Osamu Yokosuka
Journal:  Int Sch Res Notices       Date:  2014-12-16

10.  Surveillance of Levofloxacin Resistance in Helicobacter pylori Isolates in Bogotá-Colombia (2009-2014).

Authors:  Alba A Trespalacios-Rangél; William Otero; Azucena Arévalo-Galvis; Raúl A Poutou-Piñales; Emiko Rimbara; David Y Graham
Journal:  PLoS One       Date:  2016-07-25       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.